We are thrilled to announce that our collaborative project on hyperpolarised MRI calibration has secured significant grant funding. This pioneering initiative brings together NVISION and GSP, two innovative SMEs with complementary expertise, to revolutionize metabolic imaging for prostate cancer assessment.
Our project will develop the first end-to-end robust calibration process for hyperpolarised MRI across multiple centres, enabling real-time observation of metabolic processes with unprecedented clarity and consistency. By combining NVISION's scalable polarisation technology with GSP's advanced phantom development, we're creating a complete solution that will become the gold standard for top-tier imaging centres worldwide.
This breakthrough will transform how prostate cancer is assessed metabolically, providing clinicians with more reliable data for treatment decisions and opening new possibilities for personalized medicine.
We extend our gratitude to our research partners at UCL for their invaluable collaboration in this endeavour.
Together, we're making metabolic prognostication through hyperpolarised MRI accessible, reliable, and transformative for cancer care.
